This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Darzalex
  • /
  • Addition of Daratumumab to Combination of Bortezom...
Clinical trial

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Read time: 1 mins
Last updated:31st Jan 2024
Status: ACTIVE, NOT RECRUITING
Identifier: NCT02136134
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma


ClinicalTrials.gov ID: NCT02136134

Sponsor: Janssen Research & Development, LLC
Information provided by: Janssen Research & Development, LLC (Responsible Party)
Last Update Posted: 2024-02-01

Brief Summary:
The purpose of this study is to assess the effects of administration of daratumumab when combined with VELCADE (bortezomib) and dexamethasone compared with bortezomib and dexamethasone alone, for participants with relapsed or refractory multiple myeloma.

Detailed Description:
This is an open-label (physicians and participants know the identity of the assigned treatment), randomized (the study medication is assigned by chance), multicenter, active-controlled study comparing daratumumab, VELCADE, and dexamethasone (DVd) with VELCADE and dexamethasone (Vd) in participants with relapsed or refractory multiple myeloma. Approximately 480 participants will be randomly assigned in a 1:1 ratio to receive either DVd or Vd. Randomization will be stratified by International Staging System (ISS), number of prior treatment programs (1 vs. 2 or 3 vs. >3), and prior VELCADE treatment ("no" vs. "yes"). Within each stratum, participants will be randomized to one of the treatment groups.The study will consist of a Screening Phase, a Treatment Phase, and a Follow-up Phase. Participants will be treated until disease progression, unacceptable toxicity, or other reasons to discontinue the study.

Official Title:
Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma

Intervention / Treatment:
- Drug: Daratumumab
- Drug: VELCADE (Bortezomib)
- Drug: Dexamethasone

Category Value
Study Start (Actual) 2014-08-15
Primary Completion (Actual) 2016-01-11
Study Completion (Estimated) 2024-06-30
Enrollment (Actual) 498
Study Type Interventional
Phase Phase 3
Other Study ID Numbers
CR103995

2014-000255-85 (EudraCT Number)

54767414MMY3004 (Other Identifier) (OTHER: Janssen Research & Development, LLC)


View full details